Table 1.
Baseline characteristics of patients in the modified ITT population
| SMT [n = 33] | HT [n = 30] | |
|---|---|---|
| Age group | ||
| • 12–18 years [n, %] | 2 [6%] | 3 [10%] |
| • 18–65 years [n, %] | 31 [94%] | 27 [90%] |
| Age, years [mean, SD] | 35.7 [11.9] | 32.8 [13.0] |
| Males [n,%] | 4 [12%] | 7 [23%] |
| Smoking [n, %] | 6 [18%] | 7 [23%] |
| Body mass index [kg/m2, mean, SD] | 23.5 [4.1] | 23.0 [4.7] |
| Duration of IBD [years, median, IQR] | 8 [2–12] | 5 [2–10] |
| Faecal calprotectin [µg/g, median, IQR] | 32[8–53] | 39 [20–61] |
| IBS-subtype [n, %] | ||
| • Diarrhoea-predominant IBS [IBS-D] | 15 [45%] | 15 [50%] |
| • Constipation-predominant IBS [IBS-C] | 6 [18%] | 3 [10%] |
| • Mixed-type IBS [IBS-M] | 2 [6%] | 2 [7%] |
| • Unsubtyped IBS [IBS-U] | 10 [30%] | 10 [33%] |
| Duration of IBS-type symptoms [years, median, IQR] | 9 [3–15] | 8 [3–16] |
| Crohn’s disease subgroup [n, %]: | 19 [58%] | 16 [53%] |
| Age at diagnosis [n] | ||
| • A1: 0 to <10 years | 3 | 4 |
| • A2: 17–40 years | 15 | 11 |
| • A3: >40 years | 1 | 1 |
| Location [n] | ||
| • L1: ileal disease | 6 | 7 |
| • L2: ileocolonic disease | 7 | 7 |
| • L3: colonic disease | 6 | 2 |
| • L4: upper gastrointestinal disease | 2 | 3 |
| Behaviour [n] | ||
| • B1: non-stricturing, non-penetrating | 16 | 14 |
| • B2: structuring | 1 | 2 |
| • B3: penetrating | 2 | 0 |
| • P: perianal disease | 3 | 1 |
| Ulcerative colitis subgroup [n, %]: | 14 [42%] | 14 [47%] |
| Extent [n] | ||
| • E1: proctitis | 5 | 1 |
| • E2: left-sided disease | 5 | 5 |
| • E3: extensive disease | 4 | 8 |
SMT, standard medical treatment; HT, hypnotherapy; SD, standard deviation; IBD, inflammatory bowel disease; IQR, interquartle range; IBS, irritable bowel syndrome.